Evoke Pharma (NASDAQ:EVOK) posted its earnings results on Thursday. The specialty pharmaceutical company reported ($0.09) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.03, Bloomberg Earnings reports.
EVOK stock traded down $0.02 during trading on Friday, hitting $0.89. 387,152 shares of the company’s stock traded hands, compared to its average volume of 1,411,318. Evoke Pharma has a 52 week low of $0.50 and a 52 week high of $3.40. The firm has a fifty day simple moving average of $0.86.
Several research firms have commented on EVOK. ValuEngine upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, July 30th. Finally, HC Wainwright reiterated a “hold” rating on shares of Evoke Pharma in a research report on Friday.
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
See Also: How is a Moving Average Calculated?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.